What happened
DoH and Isomorphic Labs signed a 24‑month agreement to develop a pre‑clinical research roadmap for AI‑enabled drug discovery projects using Isomorphic Labs’ IsoDDE engine, a foundation‑model‑based drug design platform. The work will be conducted within Abu Dhabi’s Trusted Research Environment and will focus on diseases where Middle Eastern genomic data are under‑represented. In parallel, DoH and wearable‑tech company WHOOP launched a two‑year research programme to assess how continuous health metrics and coaching can improve cardiometabolic outcomes for adults with obesity and hypertension. The first six‑month study will track , waist circumference, heart rate, blood pressure, cholesterol, blood sugar and sleep. Finally, DoH, Cleveland Clinic Abu Dhabi and AstraZeneca announced a collaboration to host up to 30 clinical trials in Abu Dhabi by 2030, targeting cardiovascular, renal and metabolic diseases, with an estimated AED 180 million (US $50 million) investment and the first six trials slated to start by the end of 2026.
The agreement with Isomorphic Labs was signed by DoH Undersecretary Dr. Noura Khamis Al Ghaithi and Isomorphic Labs President Max Jaderberg at the Abu Dhabi Future Health Summit. The collaboration will create a roadmap for AI‑enabled pre‑clinical projects over two years, using the IsoDDE engine that combines foundational AI models to predict molecular interactions with high accuracy. Research will be hosted in Abu Dhabi’s Trusted Research Environment, ensuring data security and compliance with local regulations.
DoH’s partnership with WHOOP, represented by WHOOP Founder and CEO Will Ahmed, will run a phased 24‑month study on heart and metabolic health. The initial six‑month study will enroll adults with obesity and high blood pressure, measuring the impact of continuous wearable data and coaching on , waist circumference, heart rate, blood pressure, cholesterol, blood sugar and sleep. Physicians in Abu Dhabi will oversee study design and data handling, adhering to data‑minimisation and transparent processing standards.
The clinical‑trial collaboration involving DoH, Cleveland Clinic Abu Dhabi and AstraZeneca was announced by DoH Chairman Mansoor Ibrahim Al Mansoori. It aims to evaluate the feasibility of up to 30 trials by 2030 across AstraZeneca’s biopharmaceutical portfolio, focusing on cardiovascular, renal and metabolic diseases. The partnership is expected to inject roughly AED 180 million (US $50 million) into Abu Dhabi’s life‑sciences ecosystem, with the first six trials planned to commence at Cleveland Clinic Abu Dhabi before the end of 2026.
Source details: bignewsnetwork.com ↗
Why it matters
The DoH‑Isomorphic Labs pact brings cutting‑edge AI drug‑design technology to a region that has historically been under‑represented in genomic datasets, potentially accelerating the discovery of therapies tailored to Middle Eastern populations. By leveraging Abu Dhabi’s population‑scale genomic programme and a secure research environment, the collaboration could improve predictive fidelity of AI models and shorten pre‑clinical timelines. The WHOOP partnership illustrates a growing trend of integrating wearable data into public‑health strategies, offering real‑world evidence on how continuous monitoring can inform personalized preventive care. The AstraZeneca‑Cleveland Clinic deal positions Abu Dhabi as a strategic hub for multinational clinical trials, promising significant investment, capacity‑building for local researchers, and faster access to innovative medicines for regional patients.
AI‑driven drug discovery can dramatically reduce the time and cost of bringing new medicines to market. By applying Isomorphic Labs’ IsoDDE platform to regional genomic data, the DoH aims to generate candidate therapies that are more relevant to the genetic makeup of Middle Eastern populations, addressing a known gap in global drug development pipelines.
Wearable‑based preventive health research represents a shift from reactive to proactive healthcare. If WHOOP’s pilot demonstrates measurable improvements in cardiometabolic risk factors, it could justify broader integration of continuous health monitoring into national health strategies, potentially lowering the burden of chronic disease.
Hosting multinational clinical trials enhances Abu Dhabi’s reputation as a research hub, attracts foreign investment, and provides local patients earlier access to innovative treatments. The projected AED 180 million investment will also bolster research infrastructure, training, and regulatory expertise within the emirate.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
Which component of an AI application is the machine-learning model itself?
What to watch next
Key indicators to monitor include: (1) the first AI‑driven discovery milestones reported by Isomorphic Labs, such as candidate molecules identified or pre‑clinical validation results; (2) health outcomes from the WHOOP pilot, especially changes in cardiometabolic biomarkers and participant adherence; (3) the launch timeline and enrollment numbers for the initial six AstraZeneca trials at Cleveland Clinic Abu Dhabi; and (4) any regulatory adaptations or data‑governance frameworks introduced by DoH to support AI‑enabled research, which could set precedents for other jurisdictions.
Progress reports from Isomorphic Labs on AI‑generated drug candidates, including any pre‑clinical validation milestones.
Interim results from the WHOOP pilot, particularly changes in biometric markers and participant adherence rates.
Launch dates, enrollment figures, and early safety/efficacy data from the first six AstraZeneca trials at Cleveland Clinic Abu Dhabi.
Regulatory updates from DoH concerning AI‑enabled research, data governance policies, and any new frameworks that could influence future collaborations.